145 related articles for article (PubMed ID: 31105295)
21. Intravesical mitomycin C for superficial transitional cell carcinoma.
Bolenz C; Cao Y; Arancibia MF; Trojan L; Alken P; Michel MS
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1273-82. PubMed ID: 16925493
[TBL] [Abstract][Full Text] [Related]
22. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update.
Rouprêt M; Babjuk M; Compérat E; Zigeuner R; Sylvester RJ; Burger M; Cowan NC; Böhle A; Van Rhijn BW; Kaasinen E; Palou J; Shariat SF
Eur Urol; 2015 Nov; 68(5):868-79. PubMed ID: 26188393
[TBL] [Abstract][Full Text] [Related]
23. Magnetic Resonance Imaging Evaluation of Urothelial Cell Carcinoma: Histopathological Correlation, Staging, and Treatment Planning.
Harri PA; Alexander L; Camacho JC; Moreno CC; Mittal P
Curr Probl Diagn Radiol; 2018; 47(1):28-41. PubMed ID: 28571907
[No Abstract] [Full Text] [Related]
24. [Bladder carcinosarcoma: chondrosarcoma plus urothelial carcinoma].
Medina Pérez M; Valpuesta Fernández I; Valero Puerta J
Arch Esp Urol; 1998 Dec; 51(10):1037-9. PubMed ID: 9951129
[TBL] [Abstract][Full Text] [Related]
25. Symptoms Control for Patients with Superficial Bladder Cancers Before and After TURBT and Intravesical Epirubicin Instillation.
Gezginci E; Yyigun E; Yalcin S; Ozgok IY
Urol Nurs; 2017; 37(1):31-5. PubMed ID: 29240363
[TBL] [Abstract][Full Text] [Related]
26. Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder.
Halachmi S; Moskovitz B; Maffezzini M; Conti G; Verweij F; Kedar D; Sandri SD; Nativ O; Colombo R
Urol Oncol; 2011; 29(3):259-64. PubMed ID: 19395285
[TBL] [Abstract][Full Text] [Related]
27. [Urothelial carcinoma in bladder diverticulum. Case contribution].
Bighi S; Lupi L; Limone GL; Carluccio GC; Daniele C
Radiol Med; 1988; 75(1-2):123-5. PubMed ID: 3279468
[No Abstract] [Full Text] [Related]
28. [pT1G3 bladder carcinoma: our experience].
Dell'Orto P; Trinchieri A; D'Addezio F; Bernardini P; Mangiarotti B; Del Nero A; Pisani E
Arch Ital Urol Androl; 1996 Feb; 68(1):9-11. PubMed ID: 8664927
[TBL] [Abstract][Full Text] [Related]
29. Urothelial papilloma: a rare cause of gross haematuria in childhood.
Ribeiro A; Pereira M; Reis A; Ferreira G
BMJ Case Rep; 2017 May; 2017():. PubMed ID: 28501826
[TBL] [Abstract][Full Text] [Related]
30. Superficial bladder tumours: recurrence and progression.
Mansoor M; Ali S; Fasihuddin Q; Baloch MU
J Coll Physicians Surg Pak; 2011 Mar; 21(3):157-60. PubMed ID: 21419022
[TBL] [Abstract][Full Text] [Related]
31. Metachronous bladder metastases of a type 2 papillary renal cell carcinoma: a case report and review of the literature.
Gajasinghe DG; Nazeer I; Maddumage HP; Perera C; Abeygunasekera AM
World J Surg Oncol; 2016 Aug; 14(1):219. PubMed ID: 27549183
[TBL] [Abstract][Full Text] [Related]
32. Role of low-mechanical index CEUS in the differentiation between low and high grade bladder carcinoma: a pilot study.
Li Q; Tang J
Ultraschall Med; 2012 Feb; 33(1):87-8; author reply 88-9. PubMed ID: 21959993
[No Abstract] [Full Text] [Related]
33. [Management of non invasive bladder cancers. T1Ga urothelial cell carcinoma: benefit of immediate post operative instillation?].
Rouprêt M; Guillotreau J; Irani J; Zerbib M
Prog Urol; 2010 Mar; 20 Suppl 1():S46-9. PubMed ID: 20493444
[TBL] [Abstract][Full Text] [Related]
34. Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C.
Xylinas E; Kent M; Dabi Y; Rieken M; Kluth LA; Al Hussein Al Awamlh B; Ouzaid I; Pycha A; Comploj E; Svatek RS; Lotan Y; Karakiewicz PI; Holmang S; Shariat SF
Urol Oncol; 2018 Mar; 36(3):89.e1-89.e5. PubMed ID: 29221642
[TBL] [Abstract][Full Text] [Related]
35. Over expression of metallothionein predicts resistance of transitional cell carcinoma of bladder to intravesical mitomycin therapy.
Lynn NN; Howe MC; Hale RJ; Collins GN; O'Reilly PH
J Urol; 2003 Feb; 169(2):721-3. PubMed ID: 12544351
[TBL] [Abstract][Full Text] [Related]
36. [Mitomycin-C 30 mg for 12 months versus Mitomycin-C 40 mg for 6 months in the prevention of superficial bladder carcinoma G1-G2].
Vecchioli Scaldazza C
Minerva Urol Nefrol; 1996 Dec; 48(4):203-6. PubMed ID: 9005589
[TBL] [Abstract][Full Text] [Related]
37. Intravesical thermo-chemotherapy based on conductive heat: a first pharmacokinetic study with mitomycin C in superficial transitional cell carcinoma patients.
Milla P; Fiorito C; Soria F; Arpicco S; Cattel L; Gontero P
Cancer Chemother Pharmacol; 2014 Mar; 73(3):503-9. PubMed ID: 24442034
[TBL] [Abstract][Full Text] [Related]
38. WITHDRAWN: Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T I bladder cancer.
Shelley M; Court JB; Kynaston HG; Wilt TJ; Coles B; Mason M
Cochrane Database Syst Rev; 2015 Nov; (11):CD003231. PubMed ID: 26544085
[No Abstract] [Full Text] [Related]
39. The First Report of Urothelial (Clear Cell Variant) Bladder Cancer in a Child.
Minkowitz SY; Wadee R; Adam A
Urology; 2016 Nov; 97():204-207. PubMed ID: 27211927
[TBL] [Abstract][Full Text] [Related]
40. Urothelial carcinoma in a child.
Rodriguez A; Burday D; Sexton W; Ahmad N; Pow-Sang JM
Arch Esp Urol; 2005 Jun; 58(5):473-5. PubMed ID: 16078794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
